The Office of Public Health Genomics (OPHG) provides updated and credible information on how genomic
information and family health history can improve health and influence policy and practice. We highlight
news and information on the use of genomic tests and other applications, including family health history,
in clinical and public health practice and programs, along with relevant data, policy, and legislation. We hope the update is informative to practitioners, policy makers, consumers, and researchers. Please send
your comments to: firstname.lastname@example.org.
- Promising therapy for cystic fibrosis: Phase 2 study of Kalydeco and VX-661 in combination shows promising results, Cystic Fibrosis Foundation, Apr 18
- CDC facts about cystic fibrosis [PDF 298.67 KB]
- What you need to know about cystic fibrosis, Cystic Fibrosis Foundation
- I manage cystic fibrosis by singing: one woman's inspirational story
- Cystic fibrosis is one of the core genetic conditions included in the recommended universal newborn screening panel.
- Newborn screening saves a future NBA star, Association for Public Health Laboratories, Apr 18
- Diabetes screening & diagnosis in patients with cystic fibrosis, from the CF Foundation
Phase 2 Study of Kalydeco and VX-661 in Combination Shows Promising Results
April 18, 2013
Vertex Pharmaceuticals Inc. today announced promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco™ in combination with another potential CF therapy, VX-661.
Both Kalydeco and VX-661 are designed to treat the underlying cause of CF, a faulty gene and its protein product, known as CFTR.
“Today’s announcement is more terrific news for the CF community,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “These results show that another potential therapy from our ongoing collaboration with Vertex can be paired with Kalydeco and achieve promising improvements in health. The data further validate our strategy of using small molecule compounds to address the basic genetic defect in cystic fibrosis.”
The results showed a significant improvement in lung function in people with two copies of the most common CF mutation, Delta F508, who took the combination treatment, compared with those who received a placebo.
About 50 percent of people with CF in the United States have two copies of the Delta F508 mutation.
The Phase 2 study enrolled 128 people ages 18 and older with two copies of the Delta F508 mutation of CF. Four different doses of VX-661 were evaluated in combination with Kalydeco. Those who received the two highest doses of VX-661 showed the greatest improvement in lung function.
VX-661 is the second potential therapy that Vertex has studied in combination with Kalydeco in people with two copies of the Delta F508 mutation. Vertex is also studying Kalydeco with VX-809 in two Phase 3 trials that will enroll about 1,000 people at approximately 200 clinical trial sites in North America, Europe and Australia.
Vertex plans to conduct additional studies of VX-661 and Kalydeco in combination, pending discussions with regulatory agencies.
In today’s announcement, Vertex also said it plans to begin a Phase 1 study later this year to evaluate Kalydeco in combination with the potential CF drug VX-983 in people with two copies of the Delta F508 mutation.
The CF Foundation played a key role in the development of Kalydeco, VX-809, VX-661 and VX-983, providing significant scientific, clinical and financial support. The U.S. Food and Drug Administration approved Kalydeco in January 2012 for people with the G551D mutation of CF.
"The CF Foundation is deeply grateful to the people with CF, families and medical professionals who have played a role in these studies, and to the Vertex scientists who remain dedicated to advancing CF drug development," said Beall.